In the News
GNS Healthcare, MMRF Bring Patient Simulations to Multiple Myeloma Precision Treatment, Trial Design
Precision Oncology News reporter discusses Gemini and its prospective impact on multiple myeloma. Read more here.
read more
GNS Healthcare Launches Computer Model of Disease Progression, Treatment Responses in Myeloma
Myeloma Research News covers GNS launch of Gemini. Read more here.
read more
Wall Street Journal Covers GNS Launch of Gemini
This is the first AI-based virtual patient for multiple myeloma, said Colin Hill, the Cambridge, Mass.-based company’s co-founder and chief executive. It is traditionally difficult to predict how specific drugs or combinations of drugs might help individual multiple...
read moreEvents
Colin Hill to Speak at MassBio’s State of Possible Conference
This year’s State of Possible Conference, MassBio's Annual Meeting, will celebrate what’s possible in our industry and for patients today that wasn’t five or 10 years ago. The two-day event will draw over 600 industry leaders from Massachusetts and beyond to debate...
read more
Iya Khalil to Weigh in on How AI is Transforming Early-Stage Biotech Partnerships and Drug Discovery
Artificial Intelligence (AI) and Machine Learning (ML) are rapidly transforming industries, from autonomous cars, to logistics, to technology – and now biotechnology. Excitement about AI and ML driven solutions for accelerated drug discovery, drug development, and...
read more
GNS Co-founders to speak at Elsevier’s first AI and Big Data in Cancer Conference
The future of medicine is data-driven and AI-enabled. Artificial intelligence will impact diagnosis, treatment decisions and patient care. Learn from others along the value-chain to understand how to effectively translate technology, data and analytic innovations into...
read morePress Releases
GNS Healthcare Presents Novel Use of AI to Identify Drivers of Response to Immune Checkpoint Inhibitor Therapy
AI-driven in silico patients used to accurately identify types of immune responses in head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC). CAMBRIDGE, Mass.– [July 21, 2020] – GNS Healthcare (GNS), a leading AI and simulation company,...
read moreGNS Healthcare Launches Gemini, the First In Silico Patient for Multiple Myeloma
A transformative innovation GeminiTM, the in silico patient, will drive better drug development, clinical trial design and generation of real-world evidence in multiple myeloma GNS Healthcare, an AI-driven precision medicine company, today announced the launch of...
read moreGNS Healthcare and Multiple Myeloma Research Foundation (MMRF) Announce a Five-Year Collaboration to Advance Precision Medicine
Partnership Aims to Answer Key Questions in Multiple Myeloma Patient Care and Accelerate Discovery and Development of New Treatments Cambridge, MA – June 18, 2020-- GNS Healthcare and the Multiple Myeloma Research Foundation (MMRF) today announced a five-year...
read more